Innoviva, Inc Stock News

European cities plead for more flu shots as winter looms, pandemic rages

The GSK share price is too cheap, says Roland Head. He explains why he thinks plans to split the company will deliver gains for shareholders.

Teva Respiratory, LLC, an affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that the company is collaborating wit

Adial is a tiny microcap attempting to convert an approved nausea and sickness treatment, Ondansetran, into a treatment for alcohol use disorder.

Aurinia Pharmaceuticals is a late-stage clinical biopharmaceutical company aiming to develop and commercialize therapies for Lupus Nephritis (LN) and Dry Eye Syndrome (DES).

Despite years of research and billions of dollars spent on drug discovery, 90% of the efforts fail.

This FTSE 100 heavyweight has lost almost £14bn of market value in 12 months. What would I do with my shares now: buy, hold or sell out?

Shares in this FTSE 100 champion are down 16% in a year! But would I buy big today?

Jean Stéphenne, fringant septuagénaire vétéran du secteur pharmaceutique, a vécu en tant que président du développeur allemand de vaccins, CureVac, les montagnes russes mondiales à propos du c

Names from across the arts, sport, politics and science are among those recognised

Moncef Slaoui explains how a public-private partnership is overcoming technical and bureaucratic obstacles to find a way of inoculating against Covid.

GlaxoSmithKline is in one of its best positions in recent history, with strong financials, a very diversified business and potential for big upside.

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced 96-we